Population-Based Study of Human Papillomavirus Infection and Cervical Neoplasia in Rural Costa Rica

Rolando Herrero, Allan Hildesheim, Concepcion Bratte, Mark E. Sherman, Martha L. Hutchinson, Jorge Morales, Ileana Balmaceda, Mitchell Greenberg, Mario Alfaro, Robert D. Burk,

Obstetrical & Gynecological Survey · 2000 · 61 citations · 35 references

Concepts

TL;DR

Human papillomavirus (HPV) is the main cause of cervical neoplasia. The study aimed to estimate the prevalence of HPV infection and the risk associated with various HPV types in a high‑risk population. The authors screened 9,175 women and tested 3,024 for over 40 HPV types using PCR. They found that HPV infection peaks in women under 25 and over 55, LSILs decline with age, HSILs peak at 30 and 65, HPV16 dominates high‑grade lesions and cancers with odds ratios up to 710, and that 80 % of carcinogenic HPVs are characterized, indicating that polyvalent vaccines could prevent most cervical disease in this region.

Abstract

Human papillomavirus (HPV) is the main cause of cervical neoplasia. Because few population-based studies have investigated the prevalence of type-specific infection in relation to cervical disease, we studied a high-risk population, estimating the prevalence of HPV infection and the risk associated with various HPV types.We screened 9175 women in Guanacaste, Costa Rica, to obtain a referent standard final diagnosis, and tested 3024 women for more than 40 types of HPV with a polymerase chain reaction-based system.Among women with normal cytology, HPV infections peaked first in women younger than 25 years, and they peaked again at age 55 years or older with predominantly non-cancer-associated types of HPV and uncharacterized HPV types. Low-grade squamous intraepithelial lesions (LSILs) (n = 189) decreased consistently with age. The prevalence of high-grade squamous intraepithelial lesions (HSILs) (n = 128) peaked first around age 30 years and again at age 65 years or older. Seventy-three percent of LSILs were HPV positive, with HPV16 being the predominant type (16% of positive subjects). HPV was found in 89% of HSILs and 88% of cancers, with HPV16 being strongly predominant (51% and 53% of positive subjects). Virtually all HSILs and cancers had cancer-associated HPV types, with high odds ratios (ORs) and attributable fractions around 80%. Risk for HPV16 was particularly high (OR for HSILs = 320, 95% confidence interval [CI] = 97-1000; OR for cancer = 710, 95% CI = 110-4500).We confirm the early decline of HPV infection with age but note increased prevalence after menopause, which could be related to a second peak of HSILs, an observation that warrants further investigation. At least 80% of HPVs involved in cervical carcinogenesis in this population have been characterized. Polyvalent vaccines including the main cancer-associated HPV types may be able to prevent most cases of cervical disease in this region.

References

35